LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Abroad (travel likely)RecruitingPHASE2

Conditions

Pulmonary Hypertension Due to Lung Diseases and Hypoxia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • University of Arizona, Tucson, Arizona, United States

    Contact: Study coordinator (OrphAI Therapeutics) · aclinical@orphai-therapeutics.com
    Contact: Principal Investigator (Franz Rischard, DO)
  • Yale New Haven Hospital, New Haven, Connecticut, United States

    Contact: Study coordinator (OrphAI Therapeutics) · aclinical@orphai-therapeutics.com
    Contact: Principal Investigator (Phillip Joseph, MD)
  • Brigham and Women's Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (OrphAI Therapeutics) · aclinical@orphai-therapeutics.com
    Contact: Principal Investigator (Benjamin Stump, MD)